Lyrica

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Upjohn EESV

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics, Druge antiepileptics

Therapeutic area:

Epilepsy; Anxiety Disorders; Neuralgia

Therapeutic indications:

Nevropatske painLyrica je primerna za zdravljenje periferne in centralne nevropatske bolečine pri odraslih. EpilepsyLyrica je označen kot adjunctive terapija pri odraslih z delni epileptični napadi z ali brez sekundarne posplošitev. Splošne anksioznosti disorderLyrica je primerna za zdravljenje splošne anksiozne motnje (GAD) pri odraslih.

Product summary:

Revision: 61

Authorization status:

Pooblaščeni

Authorization date:

2004-07-05

Patient Information leaflet

                                43
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Upjohn EESV
Rivium Westlaan 142
2909 LD Capelle aan den IJssel
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/04/279/001-005
EU/1/04/279/026
EU/1/04/279/036
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Lyrica 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
44
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA S PLASTENKO ZA 25 MG TRDE KAPSULE – PAKIRANJE PO 200
1.
IME ZDRAVILA
Lyrica 25 mg trde kapsule
pregabalin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena trda kapsula vsebuje 25 mg pregabalina.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo monohidrat. Pred uporabo preberite priloženo
navodilo!
4.
FARMACEVTSKA OBLIKA IN VSEBINA
200 trdih kapsul
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
za peroralno uporabo
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
45
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Upjohn EESV
Rivium Westlaan 142
2909 LD Capelle aan den IJssel
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/04/279/046
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Lyrica 25 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
46
PODATKI, KI MOR
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Lyrica 25 mg trde kapsule
Lyrica 50 mg trde kapsule
Lyrica 75 mg trde kapsule
Lyrica 100 mg trde kapsule
Lyrica 150 mg trde kapsule
Lyrica 200 mg trde kapsule
Lyrica 225 mg trde kapsule
Lyrica 300 mg trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Lyrica 25 mg trde kapsule
Ena trda kapsula vsebuje 25 mg pregabalina.
Lyrica 50 mg trde kapsule
Ena trda kapsula vsebuje 50 mg pregabalina.
Lyrica 75 mg trde kapsule
Ena trda kapsula vsebuje 75 mg pregabalina.
Lyrica 100 mg trde kapsule
Ena trda kapsula vsebuje 100 mg pregabalina.
Lyrica 150 mg trde kapsule
Ena trda kapsula vsebuje 150 mg pregabalina.
Lyrica 200 mg trde kapsule
Ena trda kapsula vsebuje 200 mg pregabalina.
Lyrica 225 mg trde kapsule
Ena trda kapsula vsebuje 225 mg pregabalina.
Lyrica 300 mg trde kapsule
Ena trda kapsula vsebuje 300 mg pregabalina.
Pomožna snov z znanim učinkom:
Lyrica 25 mg trde kapsule
Ena trda kapsula vsebuje tudi 35 mg laktoze monohidrata.
Lyrica 50 mg trde kapsule
Ena trda kapsula vsebuje tudi 70 mg laktoze monohidrata.
Lyrica 75 mg trde kapsule
Ena trda kapsula vsebuje tudi 8,25 mg laktoze monohidrata.
Lyrica 100 mg trde kapsule
Ena trda kapsula vsebuje tudi 11 mg laktoze monohidrata.
Lyrica 150 mg trde kapsule
Ena trda kapsula vsebuje tudi 16,50 mg laktoze monohidrata.
Lyrica 200 mg trde kapsule
Ena trda kapsula vsebuje tudi 22 mg laktoze monohidrata.
3
Lyrica 225 mg trde kapsule
Ena trda kapsula vsebuje tudi 24,75 mg laktoze monohidrata.
Lyrica 300 mg trde kapsule
Ena trda kapsula vsebuje tudi 33 mg laktoze monohidrata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
trde kapsule
Lyrica 25 mg trde kapsule
Bela kapsula, ki ima na pokrovčku kapsule s črnim črnilom izpisano
oznako “VTRS”, na telesu
kapsule pa “PGN 25”.
Lyrica 50 mg trde kapsule
Bela kapsula, ki ima na pokrovčku kapsule s črnim črnilom izpisano
oznako “VTRS”, na telesu
kapsule pa “PGN 50”. Telo je poleg tega označeno s črno črto.
Lyrica 75 mg
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-02-2024
Public Assessment Report Public Assessment Report Bulgarian 17-03-2023
Patient Information leaflet Patient Information leaflet Spanish 28-02-2024
Public Assessment Report Public Assessment Report Spanish 17-03-2023
Patient Information leaflet Patient Information leaflet Czech 28-02-2024
Public Assessment Report Public Assessment Report Czech 17-03-2023
Patient Information leaflet Patient Information leaflet Danish 28-02-2024
Public Assessment Report Public Assessment Report Danish 17-03-2023
Patient Information leaflet Patient Information leaflet German 28-02-2024
Public Assessment Report Public Assessment Report German 17-03-2023
Patient Information leaflet Patient Information leaflet Estonian 28-02-2024
Public Assessment Report Public Assessment Report Estonian 17-03-2023
Patient Information leaflet Patient Information leaflet Greek 28-02-2024
Public Assessment Report Public Assessment Report Greek 17-03-2023
Patient Information leaflet Patient Information leaflet English 28-02-2024
Public Assessment Report Public Assessment Report English 17-03-2023
Patient Information leaflet Patient Information leaflet French 28-02-2024
Public Assessment Report Public Assessment Report French 17-03-2023
Patient Information leaflet Patient Information leaflet Italian 28-02-2024
Public Assessment Report Public Assessment Report Italian 17-03-2023
Patient Information leaflet Patient Information leaflet Latvian 28-02-2024
Public Assessment Report Public Assessment Report Latvian 17-03-2023
Patient Information leaflet Patient Information leaflet Lithuanian 28-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-02-2024
Public Assessment Report Public Assessment Report Lithuanian 17-03-2023
Patient Information leaflet Patient Information leaflet Hungarian 28-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 28-02-2024
Public Assessment Report Public Assessment Report Hungarian 17-03-2023
Patient Information leaflet Patient Information leaflet Maltese 28-02-2024
Public Assessment Report Public Assessment Report Maltese 17-03-2023
Patient Information leaflet Patient Information leaflet Dutch 28-02-2024
Public Assessment Report Public Assessment Report Dutch 17-03-2023
Patient Information leaflet Patient Information leaflet Polish 28-02-2024
Public Assessment Report Public Assessment Report Polish 17-03-2023
Patient Information leaflet Patient Information leaflet Portuguese 28-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 28-02-2024
Public Assessment Report Public Assessment Report Portuguese 17-03-2023
Patient Information leaflet Patient Information leaflet Romanian 28-02-2024
Public Assessment Report Public Assessment Report Romanian 17-03-2023
Patient Information leaflet Patient Information leaflet Slovak 28-02-2024
Public Assessment Report Public Assessment Report Slovak 17-03-2023
Patient Information leaflet Patient Information leaflet Finnish 28-02-2024
Public Assessment Report Public Assessment Report Finnish 17-03-2023
Patient Information leaflet Patient Information leaflet Swedish 28-02-2024
Public Assessment Report Public Assessment Report Swedish 17-03-2023
Patient Information leaflet Patient Information leaflet Norwegian 28-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 28-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 28-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 28-02-2024
Patient Information leaflet Patient Information leaflet Croatian 28-02-2024

Search alerts related to this product

View documents history